BioCentury
ARTICLE | Clinical News

Celldex gains on breast cancer subgroup survival data

December 11, 2012 2:12 AM UTC

Celldex Therapeutics Inc. (NASDAQ:CLDX) gained $1.41 (26%) to $6.93 on Monday after reporting final survival data from the 122-patient Phase IIb EMERGE trial of its glembatumumab vedotin ( CDX-011) to treat advanced, refractory or resistant glycoprotein NMB ( GPNMB)-expressing breast cancer. Overall, CDX-011 non-significantly improved median OS (7.5 vs. 7.4 months, p=0.24) and PFS (2.1 vs. 2 months, p=0.38) vs. single agent chemotherapy of the investigator's choosing. In a subgroup of patients with high GPNMB expression, CDX-011 led to a median OS of 10 months vs. 5.7 months for chemotherapy (p=0.18) and a median PFS of 2.7 months vs. 1.5 months for chemotherapy (p=0.14). ...